Incyte Corp., of Wilmington, Del., said it earned a $25 million milestone payment from Novartis AG, of Basel, Switzerland, based on the start of a Phase II trial testing c-MET inhibitor INC280 (formerly INCB28060) as monotherapy in patients with advanced hepatocellular carcinoma

Among the pharma companies, the report found that Novartis AG, of Basel, Switzerland, will maintain its position as the world's top orphan drug company in 2018, with expected sales of $11.8 billion

At the start of the session, MacDougall described two success stories emerging from previous pitch competition panels over the years, including one firm that ended up inking a deal with Novartis AG

He cited Penn's $20 million deal with Novartis AG to develop and commercialize personalized immunotherapy in a variety of cancers using Penn's chimeric antigen receptor (CAR) technologies

It has entered a license option agreement with Basel, Switzerland-based Novartis AG's Novartis Option Fund, and has received investment from Pfizer and Novartis

Among the pharma companies, the report found that Novartis AG, of Basel, Switzerland, will maintain its position as the world's top orphan drug company in 2018, with expected sales of $11.8 billion

He cited Penn's $20 million deal with Novartis AG to develop and commercialize personalized immunotherapy in a variety of cancers using Penn's chimeric antigen receptor (CAR) technologies

It has entered a license option agreement with Basel, Switzerland-based Novartis AG's Novartis Option Fund, and has received investment from Pfizer and Novartis

Novartis AG (Basel, Switzerland) $242.5 Amended multitarget agreement allowing Novartis to take a license to develop and commercialize products directed at two pre-defined and related undisclosed targets, one on an exclusive basis and the other on a non-exclusive basis Novartis agreed to pay $3.5M, and ImmunoGen may be required to credit that fee against future milestone payments if Novartis discontinues the development of specified products under certain circumstances...Novartis AG (Basel

Novartis AG; Basel, Switzerland) $43 Dendreon sold its immunotherapy manufacturing facility in Morris Plains, N.J., to Novartis Novartis paid $43M in cash 12/21/12 Evotec AG (Hamburg, Germany) Janssen Pharmaceuticals Inc. $175 Partnership for Evotec's NMDA antagonist portfolio Deal is worth a potential $75M up to launch, plus milestones payable on further products and/or indications, and $100M in commercial milestones 12/18/12 Genmab A/S (Copenhagen, Denmark) Kyowa Hakko Kirin Co...BMS also will be

Among the other players include Novartis AG, Boehringer Ingelheim, Samsung Biologics and Teva Pharmaceuticals Industries Ltd

Basel-based Novartis AG twice extended a hearing loss research collaboration and license agreement with vaccine developer GenVec Inc., of Gaithersburg, Md

Basel-based Novartis AG twice extended a hearing loss research collaboration and license agreement with vaccine developer GenVec Inc., of Gaithersburg, Md

in major indications. (See BioWorld Today, Oct. 28, 2011.) Portola had several additional partnerships, including a potential $575 million deal with Novartis AG for elinogrel, another antithrombotic program, and a potential $470 million partnership with Merck AG for betrixaban. (See BioWorld Today, Feb. 13, 2009, and July 10, 2009.) Merck handed back rights to betrixaban in 2011, citing a reprioritization of its late-stage investigational portfolio

in major indications. (See BioWorld Today, Oct. 28, 2011.) Portola had several additional partnerships, including a potential $575 million deal with Novartis AG for elinogrel, another antithrombotic program, and a potential $470 million partnership with Merck AG for betrixaban. (See BioWorld Today, Feb. 13, 2009, and July 10, 2009.) Merck handed back rights to betrixaban in 2011, citing a reprioritization of its late-stage investigational portfolio

Inc. (Whitehouse Station, N.J.) Tredaptive Extended-release niacin/laropiprant To reduce vascular events The composite primary endpoint of major vascular events occurred in only 13.2% of patients taking Tredaptive plus statin therapy compared to 13.7% of patients taking statin therapy alone 3/12/13 Novartis AG (Basel, Switzerland) Ilaris Canakinumab Gouty arthritis European Commission approved it 3/5/13 Novartis AG (Basel, Switzerland) TOBI Podhaler Tobramycin inhalation powder Cystic fibrosis

During the 2009 swine flu pandemic, Adimmune and Novartis AG, of Basel, Switzerland, were jointly awarded the rights by to produce H1N1 vaccine, with a directive to produce 10 million and 5 million doses respectively for Taiwan's local population

Novartis AG (Basel, Switzerland) Gilenya Fingolimod

Novartis AG, ending the company's 15-year quest for a patent for its cancer drug Gleevec/Glivec